HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Acute myelocytic leukemia in childhood: results of treatment from 1964 to 1979].

Abstract
From 1964 to 1979, 57 children with acute myelocytic leukemia have been treated at the University Children's Hospital, Zürich. The overall remission rate was 0.60, with a median remission duration of 2 months and survival of 6.4 months. Patients with FAB type M 1 responded best, but longtime survivors were observed from all FAB types. Whereas in the 1960s only 4/19 achieved (short) remission, now, since the introduction of cytosine arabinoside, remissions are observed on 79% but median survival (10 months) is still short compared with acute lymphocytic leukemia. However, 11/38 children treated since 1971 survived for more than 2 years. Four of these relapsed (after less than 23 months of complete remission), while of the remaining seven, 5 have been off treatment for 5 to 77 months. This group includes children of both sexes, all ages, low and high WBS's, with organ infiltrates (excluding CNS and skin), and in whom the time taken to achieve M 1 marrow played no role. These results show that, with combination chemotherapy including cytosin arabinoside, remission can almost always be attained, but prolonged remission can be maintained only in about 1/5 of these children. The problems of maintenance treatment and CNS-prophylaxis need more attention in the future.
AuthorsH J Plüss, W H Hitzig
JournalSchweizerische medizinische Wochenschrift (Schweiz Med Wochenschr) Vol. 110 Issue 40 Pg. 1459-62 (Oct 4 1980) ISSN: 0036-7672 [Print] SWITZERLAND
Vernacular TitleDie akuten myeloischen Leukämien im Kindesalter: Behandlungsresultate 1964--1979.
PMID6944786 (Publication Type: Comparative Study, English Abstract, Journal Article)
Chemical References
  • Cytarabine
Topics
  • Adolescent
  • Child
  • Child, Preschool
  • Cytarabine (therapeutic use)
  • Female
  • Humans
  • Infant
  • Leukemia, Myeloid (drug therapy)
  • Male

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: